Hemophilia A is a hereditary bleeding disorder. It is caused by low or absent activity of clotting factor VIII, preventing blood from forming stable clots after injury, leading to spontaneous internal bleeding. It is typically inherited in an X-linked pattern. With modern care, most people can live active lives, but early recognition and preventive treatment are critical.
Doctors classify hemophilia A by how much factor VIII activity is present in the blood. Mild disease is defined as greater than 5% but less than 40% of normal activity, moderate is 1% to 5%, and severe is less than 1%. Severity closely tracks day-to-day risk: people with severe hemophilia A are prone to spontaneous joint and muscle bleeds, while those with mild disease usually bleed excessively after surgery, dental work, or significant injury. These categories guide both the urgency and intensity of treatment plans. (CDC)
The list of signs and symptoms include prolonged bleeding from cuts, swelling and pain from bleeding into large joints such as knees, ankles, and elbows, deep muscle bruising, and, in serious situations, life-threatening internal bleeds including intracranial hemorrhage. In infants, unusual bleeding with circumcision or frequent, unexplained bruising from routine activity may be early clues. Because repeated joint bleeding damages cartilage and bone, early prophylaxis aims to prevent “target joints” and long-term disability. (NIH GARD)
Diagnosis rests on blood tests. An initial screening may show a prolonged activated partial thromboplastin time (aPTT) with a normal prothrombin time (PT); specific assays then measure factor VIII activity to determine severity. Clinicians also check for von Willebrand disease when the presentation is borderline, and they may recommend genetic testing for family counseling and to help anticipate inhibitor risk. Establishing care at a comprehensive hemophilia treatment center improves outcomes and simplifies care coordination. (MedlinePlus)
Treatment has two broad aims: stop bleeds quickly and prevent them from happening. On-demand therapy uses factor VIII concentrate to raise levels during an acute bleed, while prophylaxis gives factor at regular intervals to keep levels high enough to prevent bleeding in the first place. Many patients use recombinant factor VIII products, including extended half-life options that require fewer infusions. Care teams also recommend vaccinations, dental prevention, and activity choices that protect joints while maintaining fitness. (MedlinePlus)
A major advance has been non-factor prophylaxis with emicizumab, a laboratory-made bispecific antibody that mimics the function of factor VIII and is given by subcutaneous injection weekly or less often. The U.S. Food and Drug Administration approved emicizumab for routine prophylaxis to prevent or reduce bleeding in adults and children with hemophilia A, with or without factor VIII inhibitors, expanding options for families who prefer an injection schedule over frequent IV infusions. (FDA)
People with mild hemophilia A may benefit from desmopressin in certain settings, such as dental procedures or minor surgery, because it releases stored factor VIII and von Willebrand factor from the body’s own tissues, temporarily raising clotting levels. Antifibrinolytic medicines like tranexamic acid are often added around mucosal procedures to stabilize clots. Decisions about these therapies depend on baseline factor levels, prior responses, and the bleeding site, so they are individualized by the hematology team. (NCBI Bookshelf)
Some patients develop “inhibitors,” antibodies that neutralize infused factor VIII and make standard replacement ineffective. Management may include immune tolerance induction to eliminate the inhibitor over time and the use of bypassing agents during bleeds. Emicizumab prophylaxis has become an important tool in this setting, but teams still plan carefully for major surgery or trauma. Close monitoring and early treatment of any bleed remain essential to protect joints and organs. (FDA)
Gene therapy has entered clinical practice for adults with severe hemophilia A. In 2023, the FDA approved valoctocogene roxaparvovec (Roctavian), an adeno-associated virus–based infusion intended to increase endogenous factor VIII production in eligible patients without pre-existing antibodies to the AAV5 vector. Gene therapy does not work for everyone and requires careful screening and liver monitoring, but for some it reduces bleed rates and the need for frequent prophylaxis after a single treatment. Long-term durability and retreatment strategies are active areas of study.
Prognosis has improved dramatically. With consistent prophylaxis, early treatment of bleeds, and coordinated care, many people with hemophilia A now approach a near-normal life expectancy, and children can participate safely in low-impact sports that strengthen muscles around joints. Public health data show that hemophilia A is several times more common than hemophilia B and affects tens of thousands of Americans, underscoring the importance of access to comprehensive care and emerging therapies. Staying engaged with a hemophilia center, keeping rescue medication on hand, and updating an emergency plan help families navigate everyday life with confidence.
Clarity-Spot is for informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on Clarity-Spot.